和记娱乐

CN EN
Sustainability

Sustainability

Home> Sustainability> ESG Management Practices

Business Ethics

  • 【Sino Biopharmaceutical continues to deepen the construction of the responsible supply chain】
    【Sino Biopharmaceutical continues to deepen the construction of the responsible supply chain】
    【Sino Biopharmaceutical continues to deepen the construction of the responsible supply chain】
    2023.12.27
    【Sino Biopharmaceutical continues to deepen the construction of the responsible supply chain】
    To cooperate with the international development strategy, deepen the strategic cooperation relationship of the supply chain, and play the role of core enterprises in promoting ESG management, Sino Biopharmaceutical ("the Group") has launched the Responsible Supply Chain Project ("the Project") since 2022, carried out and continued to deepen the construction of responsible supply chain system.
    In 2022, Sino Biopharmaceutical has completed the main work of phase I of the Project, formulated and published the Sino Biopharmaceutical Limited Supplier Code of Conduct and other documents, completed the ESG risk classification of suppliers, and conducted the ESG concept and requirements dissemination among all Tier 1 suppliers and key tier 2 suppliers.
    In 2023, Sino Biopharmaceutical further deepened the implementation of the Project in member enterprises. During the year, the Group's member enterprises completed the construction of the supply chain ESG management system, established the Supplier ESG Management Working Group ("the Working Group"), further improved and optimized the supplier ESG management system documents, and organized key suppliers to sign the Code of Conduct. By the end of 2023, the transmission rate of the Code of Conduct of key suppliers reached 100%, and the acceptance rate of the overall key suppliers was more than 90%.
    At the same time as system construction, Sino Biopharmaceutical focused on the capacity building of the Working Group in 2023 and organized a special training on responsible supply chain on December 27.
    The training is for the Working Group of key member companies of the Group. The content is mainly divided into two modules: the first module is basic information on responsible supply chain, focusing on concept analysis, value analysis, and industry practice, to help understand the new trend of international and industrial supply chain ESG management, and deepen the understanding of the Group's supply chain sustainable development concept. The second module is on supply chain ESG audit, which mainly focuses on the specific requirements of the Code of Conduct and the key points of ESG audit, aiming to help the Working Group initially establish the audit capacity and lay the foundation for the substantive implementation of the subsequent supplier ESG management work.
    After the training, members of the Working Group actively discussed their gains, experience, and further expectations for the Group's responsible supply chain system. In the future, Sino Biopharmaceutical will combine the development strategy, give full play to the potential energy of the enterprise, and advocate and promote the sustainable development of the value chain.
  • 2023.05.31
    【Sino Biopharmaceutical establishing anti-corruption account】
    By increasing anti-corruption efforts on all fronts, Sino Biopharmaceutical has developed a corporate culture of “being honest and healthy development” and achieved considerable results in anti-corruption and anti-fraud. In order to properly deal with the employees’ initiative to hand in and confiscate the illegal funds, the Group began to set up an “anti-corruption account” in 2021, crediting a total of more than RMB4 million, including RMB1.785 million in 2022. In respect of funds in the account, 30% is used for whistleblower rewards and 70% is used for serious illness assistance for employees and their families.
  • anti-monopoly seminars
    2023.05.31
    【Sino Biopharmaceutical conducting anti-monopoly seminars】
    On 16 August 2022, the Risk and Compliance Committee and the Legal Department of the Group jointly invited a third-party experienced lawyer to host an anti-monopoly training for all employees.
  • 2022.04.30
    【Anti-fraud Audit】
    Under the leadership of the Risk Audit Department of Sino Biopharmaceutical, the audit plan of the Group is formulated annually, and the Audit and Inspection Department of member companies coordinate with the Group in carrying out multiple rounds of audit work. The 2021 audit covers all key member companies. For the problems found in the audit process, the Group conducts in-depth investigation and deals with them according to the regulations.
  • Anti-fraud Training
    Anti-fraud Training
    2022.03.01
    【Anti-fraud Training】
    Since 2021, Sino Biopharmaceutical has carried out 11 offline integrity training sessions, covering several business lines with about 1,720 participants. In September 2021, the integrity system compilation " The Furnace Rules " was released, and the video course was released through the online learning system, forcing all employees to learn and pass the exam; All new employees are required to complete and pass a course of the Furnace Rules.
    In terms of the construction of integrity culture, in January 2022, the Group produced the integrity promotion animation "Choice", and launched the "Integrity Tianqing" wechat public account in March of the same year. The Group carries out integrity culture publicity such as interpretation of integrity related laws and regulations, case interpretation through the official account every month.
  • 2022.01.01
    【Chia Tai Tianqing Experimental Animal Welfare Protection】
    The member company of the Sino Biopharmaceutical, Chia Tai Tianqing, positively practice experimental animal welfare.
    In terms of management mechanism, Tianqing establishes Experimental Animal Ethics Committee, carried out on the experimental animal ethics work supervision, inspection and technical guidance, to ensure the use of the experimental animals meets the ethical requirements, and animal experiments are carried out through ethical review. Tianqing also establishes the laboratory animal management and use committee, to supervise, inspect and give technical guidance to the management of laboratory animals, promote the standardization of laboratory animals, and improve the management and technical level of laboratory animals.

    In terms of system documents, according to the World Organization for Animal Health "Terrestrial Animal Health Code", the State Council "Regulations on the Management of laboratory animals", the State Science and Technology Commission "Measures for the quality management of laboratory animals", the Ministry of Science and Technology "Guiding opinions on the treatment of laboratory animals" and other domestic and foreign management norms, Chia Tai Tianqing has formulated a series of management systems and operational guidelines, such as Care and Behavior Plan for Experimental Animals, Management of animal Drinking Water, Management of animal feed, Principles and Use of analgesia and analgesic method selection, to provide standardized guidance for animal ethical work.
    In terms of ethical education, Chia Tai Tianqing actively participates in professional training organized by the Laboratory Animal Association, standardize the regulation of animal experiments, ensure that the design of animal experiments passes the review of the Experimental Animal Ethics Committee, safeguard the basic rights and welfare of experimental animals, create a work atmosphere that attaches importance to animal ethics, and improve the awareness of employees to protect animal rights and welfare.